Front row, left to right: Alexandra Pichard Nielsen, director, sales & business development, Cambrex; Per Kanto, national sales manager, Sweden, AstraZeneca; Juliette White, VP of global external sourcing, AstraZeneca; Bjarne Sandberg, managing director, Cambrex Karlskoga (ribbon cutting); Fredrik Härtfelder, head of supplier management, AstraZeneca; Magnus Sjögren, head of new supply API, AstraZeneca; Päivi Tolstoy, new product project manager, Cambrex. Back row, left to right: Dean Powney, supplier director, AstraZeneca; Fredrik Stenberg, product manager, Cambrex; Tomas Sjöberg, manager, plant development & support, Cambrex; Martin Brink, supply chain lead, AstraZeneca; Jeroen Koningen, project manager, AstraZeneca; Johan Kårehag, global category manager, AstraZeneca; Stephan Haitz, VP, sales & business development, Cambrex; Mattias Magnusson, senior lean coach, AstraZeneca.
Cambrex and AstraZeneca hold ceremony to mark long-term supply agreement at Karlskoga, Sweden facility.
Cambrex Corporation, a manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients (APIs), held an opening ceremony Tuesday with AstraZeneca at its Karlskoga, Sweden site to mark the commencement of a long-term manufacturing agreement between the two companies for a key intermediate.
The announcement follows the completion in 2017 of both a large-scale, multi-purpose capacity expansion, which also includes hydrogenation capabilities, and a dedicated continuous flow production unit capable of producing multiple metric tons of high purity advanced intermediates per year at the Karlskoga facility.
“Cambrex was selected as our manufacturing partner on this long-term intermediate supply agreement as they clearly demonstrated a robust technically and commercially attractive solution, as well as having a good track record in terms of performance and delivery,” Juliette White, VP global external sourcing, AstraZeneca, commented at the ceremony.
“We will continue to invest in capabilities, technology, and appropriate capacity at the Karlskoga site in line with AstraZeneca’s ambitious targets and on-going customer demand,” Shawn Cavanagh, COO of Cambrex, said.
(Source: Cambrex Corporation)
